Epidemics of influenza occur nearly every winter and last through spring, causing an average of 226,054 influenza-related hospital admissions and 51,203 influenza-related deaths in the United States annually ([@R1]--[@R3]). Persons [\>]{.ul}65 years of age are at greater risk for serious complications of influenza and ≈90% of deaths due to influenza and pneumonia occur among this age group ([@R1],[@R4]). Taiwan, like other high-income countries, recognizes the importance of influenza vaccination and strongly recommends annual vaccination to prevent complications of influenza and reduce hospitalization rates and death in older persons ([@R5],[@R6]).

Persons [\>]{.ul}65 years of age also are at greater risk for coronary atherosclerosis and cardiovascular disease. Statin treatment in this population is crucial, but benefits and risks should guide its use ([@R7],[@R8]). In addition to cholesterol-lowering effects that provide cardiovascular benefits, statins have been shown to suppress T-cell activation and exhibit antiinflammatory and immunomodulatory properties ([@R9]--[@R12]). Few studies have investigated the effect of statins on vaccine effectiveness, but concerns have been raised that statins might interfere with the immune response to influenza vaccines and seem to reduce their effectiveness ([@R13],[@R14]). A study of 6,961 trial participants \>65 years of age from Colombia, Panama, the Philippines, and the United States showed that hemagglutination-inhibiting geometric mean titers to influenza strains were much lower in chronic statin users compared with nonusers ([@R13]). Another large-scale retrospective cohort study based on a research database covering influenza seasons for 2002--2011 in the United States revealed reduced influenza vaccine effectiveness against respiratory illness in statin users ([@R14]). By contrast, data from another retrospective 5-year cohort study of 1,403,651 statin users matched to nonusers found that use of statins around the time of influenza vaccination does not dramatically affect the risk for influenza-related visits and influenza-related hospitalizations in older adults ([@R15]). Another large-scale nationwide population study evaluated whether statin therapy reduced vaccination effectiveness in terms of influenza-associated critical illness hospitalizations and death and suggested high-dose influenza vaccines or vaccines containing adjuvants to boost the immune response might be needed in older populations ([@R16]). However, previous studies did not match cases and controls for characteristics, underlying health conditions, or concomitant drug use and did not focus on the outcomes of influenza-related critical illness and death.

We designed a large-scale, nationwide, population-based cohort study to explore heterogeneity of influenza vaccine effectiveness between statin users and nonusers among persons ≥65 years of age in Taiwan. We assessed risks for hospitalization for pneumonia and influenza, circulatory conditions, or critical illness and for in-hospital death and in-hospital death from pneumonia in this age group. We compared the vaccinated group with propensity score-matched control subjects who did not receive influenza vaccinations.

Methods
=======

Data Source
-----------

We used the data from Taiwan's National Health Insurance Research Database (NHIRD), which has been described in detail elsewhere ([@R17]--[@R19]). We extracted medical data for persons [\>]{.ul}65 years of age in Taiwan from an NHIRD dataset based on a regulation that prohibits use of the maximal amount of claims data and permits use of data from only one third of older beneficiaries for research purposes. Our dataset included information on all inpatient, emergency department, and outpatient visits; diagnosed illnesses and conditions; prescriptions; and procedures for one third of all persons [\>]{.ul}65 years of age in Taiwan. We used diagnostic and procedural codes from the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM; <https://www.cdc.gov/nchs/icd/icd9cm.htm>) to ascertain details associated with inpatient and outpatient encounters. Because patient information in the NHIRD is secondary, deidentified, and encrypted, this study was exempted from a full ethics review by the institutional review board of Taipei Medical University Hospital (IRB no. 105TMUH-SP-07).

Study Population
----------------

The study period encompassed 12 consecutive influenza seasons from 2000--01 through 2011--12 ([@R14]). The study sample was comprised of persons [\>]{.ul}65 years of age who resided in Taiwan during 2000--2012. Persons [\>]{.ul}65 years of age in Taiwan are encouraged to receive influenza vaccines, which are covered by insurance, between October 1 and December 31 each year. For our study, we defined the index date as the date of influenza vaccination for the vaccinated group. To avoid immortal time bias, for the unvaccinated group we randomly assigned index dates that corresponded to those in the vaccinated group. Because the same persons could be part of the unvaccinated group initially and later change to the vaccinated group during the influenza period each year, we did not include the unvaccinated period in our outcome analyses. In each year, we traced participants' NHIRD records from January 1 through September 30 or death.

Statin Exposure
---------------

For each year in the study period, we identified all drug prescriptions written for participants before the index date by using inpatient and ambulatory care order files. For statin users, we identified persons who had initial dispensing date of statin on or before the index date. We defined chronic statin users as those who received and filled a prescription for a statin medication for [\>]{.ul}30 days ([@R20],[@R21]).

Outcomes
--------

The outcomes of interest were in-hospital death and in-hospital death from pneumonia. Our analyses also included severe complications of influenza infections, including hospitalization for pneumonia, circulatory condition, and critical illness. We defined critical illness as hospitalization for acute respiratory failure (ICD-9-CM codes 518.5, 518.81, 518.82, or 96.7) or severe sepsis (ICD-9-CM codes 995.92 or 785.52) or organ dysfunction ([@R22]).

Statistical Analyses
--------------------

We examined the differences of baseline characteristics between the vaccinated group and unvaccinated group by using standardized mean differences. For each participant, we calculated a propensity score for the likelihood of receiving influenza vaccination by using baseline covariates in a multivariate logistic regression model ([Appendix](#SD1){ref-type="local-data"} [Table 1](#T1){ref-type="table"}). For each person in the vaccinated group, we identified 1 person in the unvaccinated group that was frequency-matched according to propensity score ([@R23]). We used Cox regression with adjusted imbalance covariates to calculate hazard ratios (HRs) for in-hospital death; in-hospital death from pneumonia; and hospitalization for pneumonia, circulatory conditions, and critical illness. We conducted a subgroup analyses and used a likelihood ratio test to explore heterogeneity of vaccine effectiveness between statin users and nonusers. We used SQL Server 2012 (Microsoft, <https://www.microsoft.com>) for data linkage, processing, and sampling. We performed all analyses by using 2-sided tests in Stata version 12.0 (StataCorp, <https://www.stata.com>) and considered p\<0.05 statistically significant.

###### Characteristics of persons [\>]{.ul}65 who received influenza vaccine versus those who did not receive influenza vaccine, Taiwan\*

  Characteristics                               Before propensity score-matching                      Propensity score-matched                                            
  --------------------------------------------- ---------------------------------- ------------------ -------------------------- -- ------------------ ------------------ ---------
  No. patients                                  3,417,212                          6,010,180                                        3,165,272          3,165,272          
  Mean age, y (SD)                              74.3 (6.4)                         73.6 (6.8)         0.100                         74.2 (6.4)         74.2 (6.9)         --0.002
  Sex                                                                                                                                                                     
  M                                             1,707,483 (50.0)                   2,908,606 (48.4)   0.031                         1,559,852 (49.3)   1,550,848 (49.0)   0.006
  F                                             1,709,729 (50.0)                   3,101,574 (51.6)                                 1,605,420 (50.7)   1,614,424 (51.0)   
  Monthly income, \$ Taiwan                                                                                                                                               
  Dependent†                                    1,234,769 (36.1)                   2,527,696 (42.1)   --0.122                       1,190,930 (37.6)   1,197,102 (37.8)   --0.004
  \<19,100                                      794,513 (23.3)                     1,365,600 (22.7)   0.013                         728,908 (23.0)     721,281 (22.8)     0.006
  19,100--41,999                                1,367,022 (40.0)                   2,054,058 (34.2)   0.121                         1,224,632 (38.7)   1,226,438 (38.7)   --0.001
  [\>]{.ul}42,000                               20,908 (0.6)                       62,826 (1.0)       --0.048                       20,802 (0.7)       20,451 (0.6)       0.001
  Urbanization‡                                                                                                                                                           
  Level 1                                       988,136 (28.9)                     1,833,258 (30.5)   --0.035                       926,242 (29.3)     925,049 (29.2)     0.001
  Level 2                                       2,194,465 (64.2)                   3,793,218 (63.1)   0.023                         2,025,556 (64.0)   2,025,109 (64.0)   0.000
  Level 3                                       199,301 (5.8)                      320,751 (5.3)      0.022                         180,635 (5.7)      181,562 (5.7)      --0.001
  Level 4                                       35,310 (1.0)                       62,953 (1.0)       --0.001                       32,839 (1.0)       33,552 (1.1)       --0.002
  No. outpatient visits in the previous 12 mo                                                                                                                             
  0--10                                         504,028 (14.7)                     1,831,616 (30.5)   --0.383                       504,014 (15.9)     500,316 (15.8)     0.003
  11--20                                        869,805 (25.5)                     1,598,542 (26.6)   --0.026                       851,438 (26.9)     854,335 (27.0)     --0.002
  21--30                                        776,389 (22.7)                     1,106,821 (18.4)   0.107                         719,783 (22.7)     721,771 (22.8)     --0.001
  31--40                                        522,170 (15.3)                     651,142 (10.8)     0.132                         462,035 (14.6)     462,408 (14.6)     0.000
  \>40                                          744,820 (21.8)                     822,059 (13.7)     0.214                         628,002 (19.8)     626,442 (19.8)     0.001
  CCI score (SD)§                               7.7 (2.8)                          7.2 (2.8)          0.236                         7.8 (2.8)          7.8 (2.9)          --0.006
  Underlying conditions                                                                                                                                                   
  Cerebrovascular disease                       1,151,954 (33.7)                   1,703,465 (28.3)   0.116                         1,047,165 (33.1)   1,052,107 (33.2)   --0.003
  Diabetes                                      1,377,596 (40.3)                   2,000,525 (33.3)   0.146                         1,246,943 (39.4)   1,252,696 (39.6)   --0.004
  Hypertension                                  2,568,836 (75.2)                   3,931,874 (65.4)   0.215                         2,344,103 (74.1)   2,351,157 (74.3)   --0.005
  CAD                                           1,672,350 (48.9)                   2,340,127 (38.9)   0.203                         1,520,516 (48.0)   1,447,015 (45.7)   0.047
  Myocardial infarction                         158,688 (4.6)                      228,094 (3.8)      0.042                         143,777 (4.5)      144,573 (4.6)      --0.001
  PVD                                           238,514 (7.0)                      324,691 (5.4)      0.065                         217,314 (6.9)      210,393 (6.6)      0.009
  Heart failure                                 555,349 (16.3)                     792,171 (13.2)     0.087                         503,135 (15.9)     506,674 (16.0)     --0.003
  Dyslipidemia                                  1,557,151 (45.6)                   2,231,936 (37.1)   0.172                         1,436,998 (45.4)   1,340,441 (42.3)   0.062
  Chronic liver disease                         1,067,001 (31.2)                   1,460,809 (24.3)   0.155                         950,911 (30.0)     951,575 (30.1)     0.000
  CKD                                           664,324 (19.4)                     917,408 (15.3)     0.110                         596,302 (18.8)     597,911 (18.9)     --0.001
  Peptic ulcer disease                          1,904,442 (55.7)                   2,764,223 (46.0)   0.196                         1,720,590 (54.4)   1,723,618 (54.5)   --0.002
  Dementia                                      249,766 (7.3)                      370,758 (6.2)      0.045                         228,856 (7.2)      231,226 (7.3)      --0.003
  Valvular heart disease                        424,657 (12.4)                     596,580 (9.9)      0.079                         383,055 (12.1)     384,592 (12.2)     --0.001
  Drug abuse                                    48,591 (1.4)                       74,326 (1.2)       0.016                         45,499 (1.4)       45,816 (1.4)       --0.001
  Atrial fibrillation                           160,148 (4.7)                      235,626 (3.9)      0.038                         146,674 (4.6)      147,989 (4.7)      --0.002
  Medications                                                                                                                                                             
  Antiplatelet agents                           559,272 (16.4)                     735,104 (12.2)     0.118                         491,897 (15.5)     493,185 (15.6)     --0.001
  Insulin                                       42,022 (1.2)                       58,973 (1.0)       0.024                         38,581 (1.2)       38,823 (1.2)       --0.001
  Oral diabetic drugs                           399,409 (11.7)                     552,935 (9.2)      0.081                         358,531 (11.3)     361,189 (11.4)     --0.003
  Diuretics                                     301,500 (8.8)                      420,868 (7.0)      0.067                         270,816 (8.6)      272,637 (8.6)      --0.002
  Calcium channel blockers                      651,895 (19.1)                     892,880 (14.9)     0.113                         580,984 (18.4)     583,106 (18.4)     --0.002
  Beta-blockers                                 413,542 (12.1)                     583,937 (9.7)      0.077                         371,599 (11.7)     372,374 (11.8)     --0.001
  ACEI/ARB                                      508,701 (14.9)                     719,943 (12.0)     0.085                         459,520 (14.5)     461,934 (14.6)     --0.002
  Statins                                       167,188 (4.9)                      249,822 (4.2)      0.035                         155,133 (4.9)      155,624 (4.9)      --0.001
  Propensity score                              0.42 (0.13)                        0.33 (0.14)        0.662                         0.406 (0.129)      0.406 (0.129)      0.000

\*Values are no. (%) except as indicated. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CAD, coronary artery disease; CCI, Charlson Comorbidity Index; CKD, chronic kidney disease; PVD, peripheral vascular disease. †Dependent persons are those without an income. ‡Urbanization levels in Taiwan are divided into 4 strata according to the Taiwan National Health Research Institute publications. Level 1 designates the most urbanized areas, and level 4 designates the least urbanized areas. §CCI score is used to determine overall systemic health. Increased CCI scores are indicative of stepwise increases in the cumulative mortality.

Results
=======

Our study included 3,417,212 persons who received influenza vaccination and 6,010,180 who were not vaccinated during 12 consecutive influenza seasons. We matched demographic characteristics and baseline underlying conditions before and after propensity score matching ([Table 1](#T1){ref-type="table"}). Before propensity score matching, the vaccinated group was older (74.3 years of age) than the unvaccinated group (73.6 years of age) and had higher Charlson Comorbidity Index scores (7.7 [+]{.ul} 2.8) than the unvaccinated group (7.2 [+]{.ul} 2.8). The vaccinated group had higher rates of diabetes mellitus (40.3% vs. 33.3%) and coronary artery disease (48.9% vs. 38.9%) than the unvaccinated group. In addition, the vaccinated group had higher proportions of use of antiplatelet agents (16.4%) than the unvaccinated group (12.2%), and more used oral medications for diabetes (11.7%) than those in the unvaccinated group (9.2%). A total of 167,188 (4.9%) persons in the vaccinated group and 249,822 (4.2%) persons in the unvaccinated group were statin users.

Incidence rates of hospitalization for pneumonia and influenza increased over time. In 2000, the incidence rate was 26.71/1,000 person-years. By 2012, the incidence rate was 41.08/1,000 person-years ([Table 2](#T2){ref-type="table"}). During 2000--2012, hospitalization for pneumonia and influenza occurred on an average of 23,595 events per year (14,272--33,428 events/year).

###### Incidence of hospitalization for pneumonia and influenza in persons [\>]{.ul}65 years of age during 2000--2012, Taiwan

  Year   No. events   Person-years   Incidence/1,000 person-years
  ------ ------------ -------------- ------------------------------
  2000   14,272       534,348        26.71
  2001   17,342       596,594        29.07
  2002   17,383       615,868        28.23
  2003   19,298       610,215        31.62
  2004   21,807       640,872        34.03
  2005   19,909       662,198        30.07
  2006   22,394       664,194        33.72
  2007   24,148       699,617        34.52
  2008   25,829       713,500        36.20
  2009   28,226       730,645        38.63
  2010   31,945       733,967        43.52
  2011   33,428       746,025        44.81
  2012   30,760       748,838        41.08

Compared with the unvaccinated group, the vaccinated group had lower risks of in-hospital death (adjusted hazard ratio \[aHR\] 0.69, 95% CI 0.68--0.69), in-hospital death from pneumonia (aHR 0.72, 95% CI 0.70--0.73), hospitalization for pneumonia and influenza (aHR 0.84, 95% CI 0.84--0.85), hospitalization for circulatory conditions (aHR 0.90, 95% CI 0.90--0.90), and hospitalization for critical illnesses (aHR 0.75, 95% CI 0.74--0.76) ([Table 3](#T3){ref-type="table"}). For subgroup analyses stratified by statin use, the effects of vaccination on in-hospital death (*P*~interaction~ = 0.478), in-hospital death from pneumonia (*P*~interaction~ = 0.493), hospitalization for pneumonia and influenza (*P*~interaction~ = 0.138), hospitalization for circulatory condition (*P*~interaction~ = 0.667), and hospitalization for critical illness (*P*~interaction~ = 0.375) were consistent among statin users and nonusers. We also analyzed these data by using the Cox regression model, adjusted for propensity score only, and noted similar results (Appendix [Table 2](#T2){ref-type="table"}).

###### Comparison of statin users and nonusers [\>]{.ul}65 years of age for incidence and risk for hospitalization, pneumonia, circulatory conditions, critical illness, and death who are vaccinated and unvaccinated for influenza, Taiwan\*

  Characteristics                                 Vaccinated               Unvaccinated (referent)      Hazard ratio (95% CI)†                                               
  ----------------------------------------------- ------------ ----------- ------------------------- -- ------------------------ ----------- -------- -- ------------------- -------------------
  In-hospital death§                              38,320       2,984,344   12.84                        55,405                   2,949,054   18.79       0.68 (0.67--0.69)   0.69 (0.68--0.69)
  Statin user                                     1,478        147,164     10.04                        22,097                   146,668     14.30       0.70 (0.66--0.75)   0.71 (0.67--0.76)
  Statin nonuser                                  36,842       2,837,180   12.99                        53,308                   2,802,386   19.02       0.68 (0.67--0.69)   0.68 (0.68--0.69)
  In-hospital death from pneumonia¶               15,057       2,984,931   5.04                         20,699                   2,950,157   7.02        0.72 (0.70--0.73)   0.72 (0.70--0.73)
  Statin user                                     503          147,202     3.42                         665                      146,723     4.53        0.75 (0.67--0.85)   0.75 (0.67--0.85)
  Statin nonuser                                  14,554       2,837,730   5.13                         20,034                   2,803,435   7.15        0.72 (0.70--0.73)   0.72 (0.70--0.73)
  Hospitalization for pneumonia or influenza\#    103,395      2,946,802   35.09                        121,776                  2,907,115   41.89       0.84 (0.83--0.84)   0.84 (0.84--0.85)
  Statin user                                     3,967        145,687     27.23                        4,810                    144,805     33.22       0.82 (0.79--0.86)   0.82 (0.79--0.86)
  Statin nonuser                                  99,428       2,801,115   35.50                        116,966                  2,762,309   42.34       0.84 (0.83--0.85)   0.84 (0.84--0.85)
  Hospitalization for circulatory condition\*\*   394,245      2,801,412   140.73                       430,954                  2,750,954   156.66      0.90 (0.90--0.90)   0.90 (0.90--0.90)
  Statin user                                     25,141       134,914     186.35                       27,991                   132,843     210.71      0.89 (0.87--0.90)   0.90 (0.88--0.91)
  Statin nonuser                                  369,104      2,666,498   138.42                       402,963                  2,618,111   153.91      0.90 (0.90--0.90)   0.90 (0.89--0.90)
  Hospitalization for critical illness††          62,018       2,968,927   20.89                        82,602                   2,929,804   28.19       0.74 (0.73--0.75)   0.75 (0.74--0.76)
  Statin user                                     2,614        146,432     17.85                        3,574                    145,677     24.53       0.73 (0.69--0.77)   0.74 (0.71--0.78)
  Statin nonuser                                  59,404       2,822,496   21.05                        79,028                   2,784,127   28.39       0.74 (0.73--0.75)   0.75 (0.74--0.76)

\*Values after propensity score-matching between persons who received and did not receive influenza vaccination. †Calculated by Cox regression model with adjusted imbalance covariates listed in [Table 1](#T1){ref-type="table"}. In all cases, p\<0.001. ‡Per 1,000 person-years. §Interaction p = 0.478. ¶Interaction p = 0.493. \#Interaction p = 0.138. \*\*Interaction p = 0.667. ††Interaction p = 0.375.

Discussion
==========

In this nationwide population-based study in Taiwan, we investigated the effects of statin therapy on the risks for in-hospital death and severe complications of influenza infections in 9,427,392 persons [\>]{.ul}65 years of age during influenza seasons from 2000--01 through 2011--12. We found that vaccinated groups had lower risks than unvaccinated groups for in-hospital death; in-hospital death from pneumonia; and hospitalization for pneumonia and influenza, circulatory conditions, and critical illness. In the subgroup analysis stratified by statin use, the observed outcome differences across stain users and nonusers were consistent with chance.

Statins might exert antiinflammatory effects by inhibiting the major histocompatibility complex class II pathway of antigen presentation ([@R24]), preventing accumulation and recruitment of monocytes ([@R25]), reducing cytokine production by immune cells ([@R26],[@R27]), and impairing the activation of T cells ([@R9],[@R28]). Previous studies that directly address statin use and vaccine effectiveness have had conflicting results. A randomized clinical study of 150 healthy persons failed to find any difference in antibody responses to hepatitis A vaccine among those receiving atorvastatin and those receiving a placebo ([@R29]); that study was limited because only statin therapy initiated on the day of randomization, not prior chronic statin therapy, was considered. In contrast, another study of 105,874 vaccinated persons (39,342 statin users and 66,532 nonusers) and 141,714 unvaccinated persons (52,685 statin users and 89,029 nonusers) revealed reduced influenza vaccine effectiveness against acute respiratory illness among statin users compared with nonusers during influenza seasons ([@R14]). However, that study was limited by healthy-user bias ([@R30],[@R31]) and did not match characteristics in controls.

Other large-scale studies have revealed suboptimal influenza vaccine effectiveness in persons [\>]{.ul}65 years of age because of age-related decline in the immune response, multiple underlying conditions, and concomitant medication use with possible secondary interactions ([@R32],[@R33]). To address the potential negative effects of concomitant statin therapy on vaccine effectiveness, a prior post hoc analysis showed that influenza antibody titers were much lower in those receiving chronic statin therapy compared with those not receiving statin therapy ([@R13]). However, the association between antibody titers and adverse clinical outcomes was not characterized further, raising concern about the actual clinical implications. Another population-based retrospective cohort study of 1,403,651 Medicare beneficiaries [\>]{.ul}65 years of age in the United States matched statin users to nonusers and found that statin use does not dramatically affect the risk for influenza-related visits and influenza-related hospitalizations in this population ([@R15]). However, the study did not determine whether chronic statin use had any implication for major adverse cardiovascular events or death.

We found that, among persons [\>]{.ul}65 years of age, vaccinated statin users and nonusers had lower risks of in-hospital death and severe complications of influenza infections compared with unvaccinated groups. In further analyses, we found no statistically significant difference and interaction between statin use and hospitalization for pneumonia, influenza, or circulatory conditions. However, vaccine effectiveness against critical illness slightly increased in statin users compared with nonusers, suggesting that the context of benefits of statins for cardiovascular outcomes could play a role for critically ill patients ([@R34]).

The strengths of our study include the use of a large nationwide population-based dataset, encompassing data from 9,427,392 patients [\>]{.ul}65 years of age. Our study covered 12 influenza seasons, from 2000--01 through 2011--12, aiding comparison of the effects of statins on the risks for death and hospital admission for major pulmonary and circulatory events in older vaccinated and unvaccinated persons.

Our study has some limitations. First, relevant details enabling characterization of the geographic spread of influenza activity as sporadic, local, regional, or widespread, and information on influenza virus subtypes were not available in the NHIRD dataset. Therefore, we could not identify the effects of statin therapy on the spread of influenza. Second, we used data on persons registered in the national health insurance program, which included information on adverse clinical outcomes caused by local and widespread influenza, but we cannot rule out the possibility of diagnostic misclassification. Third, with a such large sample in our study, a statistical test would easily demonstrate a significant difference. However, the risk difference in the vaccinated group compared with the unvaccinated group ranged from 10% to 31%, and the difference is not small. For subgroup analyses, the overall treatment effects also are consistent across subsets of patients. In addition, although we explored the interaction between statin use and the effectiveness of the influenza vaccine, whether other drugs exerting similar pleiotropic effects, such as aspirin and nonsteroidal antiinflammatory drugs, or other vaccines commonly used in this population, including pneumococcal and herpes vaccines, have similar interactions is unknown. Finally, our study included only persons [\>]{.ul}65 years of age, and our results cannot be extrapolated to younger persons who often elicit stronger immune responses after vaccination.

In conclusion, influenza vaccination was associated with lower risks of in-hospital death and hospitalization for pulmonary and circulatory adverse outcomes in persons [\>]{.ul}65 years of age in Taiwan. Of note, the rate of hospitalization for critical illness was slightly lower in statin users than that for nonusers. These findings indicate that influenza vaccination should continue to be encouraged in older populations because it reduces disease-specific hospitalization and death. In addition, statin use might enhance the protective effects of the vaccine against critical illness.

###### Appendix

Additional information on statin use and effectiveness of influenza vaccines in persons [\>]{.ul}65 years of age, Taiwan.
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